Mechanisms of Taxol resistance related to microtubules

George A. Orr, Pascal Verdier-Pinard, Hayley McDaid, Susan Band Horwitz

Research output: Contribution to journalReview articlepeer-review

603 Scopus citations


Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of Taxol has dramatically increased. Although treatment with Taxol has led to improvement in the duration and quality of life for some cancer patients, the majority eventually develop progressive disease after initially responding to Taxol treatment. Drug resistance represents a major obstacle to improving the overall response and survival of cancer patients. This review focuses on mechanisms of Taxol resistance that occur directly at the microtubule, such as mutations, tubulin isotype selection and post-translational modifications, and also at the level of regulatory proteins. A review of tubulin structure, microtubule dynamics, the mechanism of action of Taxol and its binding site on the microtubule are included, so that the reader can evaluate Taxol resistance in context.

Original languageEnglish (US)
Pages (from-to)7280-7295
Number of pages16
Issue number47 REV. ISS. 6
StatePublished - Oct 20 2003


  • Microtubule
  • Resistance
  • Taxol

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Mechanisms of Taxol resistance related to microtubules'. Together they form a unique fingerprint.

Cite this